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ABSTRACT 
Infection, trauma or neoplasia can lead to extensive bone tissue loss. Current 
reconstructive approaches for large, complex bone defects, especially in the maxillo-
facial region, rely on autologous bone grafting. However, reconstruction by autologous 
tissue transfer can encounter major difficulties. Not only is tissue transfer restricted by 
donor site morbidity and limited availability, the three-dimensional suitability of donor 
and recipient tissue can represent a major hurdle. To avoid these shortcomings, it 
would be of high interest to generate a prefabricated, vascularized, custom-shapeable 
bone graft. The envisioned bone graft surrogate relies on the concept of combining an 
efficient vascularization strategy with an engineered material, providing robust bone 
formation.   
In this thesis I investigate whether an arteriovenous (AV) bundle is suitable as an 
efficient vascularization method, able to fully revitalize a critically sized bone graft. In 
combination with an osteoconductive ceramic material and a living cell source, the 
stromal vascular fraction (SVF) from adipose tissue, the AV bundle is able to induce 
and support bone formation. A newly developed, contrast-enhanced, 
microtomographic imaging technique made it possible to critically assess   
vascularization and bone formation within such a graft in its entirety. Eventually, 
implementation of an engineered matrix, useable as an off-the-shelf material, in the 
above mentioned graft allowed to generate a germ of osteoinduction and 
vascularization.  
The developed concept of a prefabricated, pedicled, large bone graft, customizable to 
the patients’ needs, offers a vast variety of clinical applications.  
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1. Bone: 
The human skeleton is composed by bones, which, on the one hand give structural 
stability and protection to the vulnerable viscera through their rigid and on the other 
hand allow movement of extremities and thus locomotion. Bone is a highly dynamic 
system which takes active part in a variety of aspects of the human metabolism: it 
regulates mineral storage and supply (e.g. calcium and phosphorus), it balances pH 
fluctuations by buffering excesses and exerts detoxifying effects by storing heavy 
metals or other toxic elements [1]. Importantly, bone produces white and red blood 
cells within its bone marrow.  
Bone consists majorly of two components, collagen and calcium phosphate, albeit it is 
not uniformly solid. One can distinguish a more solid bone structure, the so-called 
cortical (compact) bone and a less dense one, termed cancellous (trabecular, spongy). 
Based on their properties the two types are found in different locations and fulfil 
different functions. Whereas compact bone is principally located in the diaphysis (shaft) 
of long bones and constitutes the outer lining thereof, the cancellous type is a porous 
trabecular network majorly present in the end of long bones (metaphysis and 
epiphysis). While the compact bone facilitates functions such as structural support and 
lever for musculoskeletal interaction, the cancellous bone hosts the bone marrow and 
gives bone flexibility through its inferior density. 
The difference in structure and function of the two bone types derives from their 
different microscopic composition. Cortical bone is highly organized: Mineralized 
collagen fibers form into sheets (lamellae) which wind around a central canal to form a 
so-called osteon or Haversian system (Fig. 1)[2]. The cylindrical osteons, with a 
diameter of about 200-250 µm, are piled one next to another, parallel to the long axis 
of the bone. Cancellous bone’s primary units are the so-called trabeculae, which are 
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arranged in an interconnecting framework aligned towards the mechanical load 
dispersion the bone experiences. Bone is home to three major active bone cell types 
all residing within the bone matrix: Osteoblasts, which create and mineralize bone, 
osteocytes, responsible for bone maintenance and osteoclasts, which resorb bone. 
 
 
Figure 1: Schematic image of bone structure.  
(http://www.mhhe.com/biosci/esp/2001_gbio/folder_structure/an/m5/s2/index.htm) 
 
  
 
 
 
1.1. Bone development:  
The process of bone formation, or ossification, occurs by two main mechanisms in 
human embryogenesis, termed intramembranous (i.e. direct) and endochondral 
(indirect) ossification (Fig. 2). While intramembranous ossification involves deposition 
of bone matrix in the mesenchyme by mesenchymal progenitor cells directly 
differentiated into osteoblasts, endochondral bone formation occurs through a 
cartilaginous precursor. Progenitor cells are recruited, condensate, proliferate and 
primarily differentiate into chondrocytes [3]. This cartilaginous matrix, called 
perichondrium at its borders and rich in Collagen II and aggrecan expresses high levels 
of SOX-9 [4–6]. Within the growing cartilaginous primordium chondrocytes stop 
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proliferating, begin to hypertrophy and synthesize primarily collagen X. Hypertrophic 
chondrocytes instruct mineralization of the matrix, secern factors supporting 
vascularization and promote both chondroclasts for degradation of cartilage and 
perichondral cells to become osteoblasts [7,8]. Eventually, the hypertrophic 
chondrocytes undergo apoptosis leaving behind a cartilaginous scaffold whereto 
osteoblasts migrate, fully remodeling the cartilage template to bone. (Fig. 3) 
 
 
 
Figure 2: The intramembranous and endochondral ossification processes. Adapted from Long et al. 2012 [7] 
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Figure 3: Endochondral ossification from mesenchymal cell condensation (a), chondrogenic differentiation thereof 
(b), transformation of perichondral cells to osteoblasts, which is defined as the bone collar (bc). Successive 
apoptosis of hypertrophic chondrocytes is accompanied by osteoblastic and vascular invasion (d&e). Proliferating 
chondrocytes elongate the bone (f) and persist (col) below the secondary ossification centers (soc) (g). Adapted 
from Kronenberg et al .2003 [9] 
 
1.2. Bone vascularization: 
Ever since early embryogenesis, when blood vessels are directed towards the newly 
forming bone by secretion of proangiogenic factors released in the matrix, bone tissue 
is a highly vascularized tissue [8,10]. The vasculature retains an important role in bone 
throughout life, not only due to its function in growth and homeostasis of the tissue but 
also during fracture healing [11]. As in other organs, vessels control the nutrient, 
oxygen and cytokine delivery to bone tissue and thus are a major limiting factor 
regarding its physiological function. Approximately 10 % of the cardiac output is 
directed to bone, which does not only reflect the high need of bone-related cells 
(osteoblasts, osteocytes and osteoclasts) and the bone marrow but also allows a high 
degree of remodeling and repair [12]. Hereby the precise anatomy of bone related 
vessels ensure steady perfusion of the bone organ:  
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In long bones the cortex is pierced by arteries in the three anatomical subdivisions: 
epiphyseal, metaphyseal and diaphyseal arteries warrant blood supply to each area 
(Fig. 4 A). Perfusion of the periosteum is ensured by periosteal vessels, arranged 
circumferentially and connected by numerous vertical anastomoses. Once the vessels 
penetrate the bone, arteries branch into arterioles and finally capillaries which allow 
metabolite exchange as it is common in the rest of the human organism [13–15]. 
However, the vasculature within bone is unique because the blood flows within a rather 
rigid cavity where pressure must be kept constant and at the same time minerals, 
hormones, blood cells and other products of the bone marrow have to be carried to the 
entire organism  [15]. Venous blood is collected in a large central sinus (Fig. 4 B), 
which can alter its volume drastically (up to five times) upon stimulation [16]. Veins, 
parallel to the bone related arteries, drain the sinusoidal blood back into the large 
venous vessels of the limbs and into systemic circulation [17].  
 
A  B  
Figure 4: Anatomical subdivision of arterial (A) and venous (B) systems suppling bone. Adapted from Laroche et 
al. 2002 [15].  
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It seems reasonable that impairment of blood supply to bone compromises both its 
development (and growth) and repair, because it deprives the tissue of essential 
nutrients and cyto- and chemokines [11,12,18–21]. Besides these metabolites, oxygen 
and hypoxia have been recognized to have a special role in bone function [12]. The 
oxygen tension within healthy bone marrow lies within the range of median interstitial 
pO2 levels of other tissues [22,23]. Since the physiological variation capability of this 
system is rather narrow, cells respond promptly to fluctuations above or below the 
range with hypoxia inducible transcription factors (HIFs) [24]. When oxygen tension 
decreases, oxygen is not available to induce degradation of HIF-a. HIF-a 
heterodimerizes with HIF-β, which initiates transcription of hypoxia-related genes 
responsible for proangiogenic processes, involving crucial mediators such as VEGF 
and PDGF [25,26]. In addition to the effect of oxygen on the molecular cascade 
affecting the transcription of proangiogenic, proliferative and metabolic factors, it also 
directly affects cells of bone tissue, i.e. osteoblasts and osteoclasts. Studies have 
shown that when pO2 levels drop below 2% bone formation nearly ceases due to a 
strong inhibitory effect of hypoxia on osteoblasts [27,28]. This restraint is due to a direct 
inhibitory effect on the proliferation and differentiation of the osteoblasts as well as to 
a reduction of collagen production elicited by decreased activity of enzymes required 
for post-translational modification of the protein. The inhibitory activity of hypoxia on 
osteoblasts is accentuated by an enhancing effect on their counterpart – the 
osteoclasts, which thrive under hypoxic conditions. In contrast to osteoblasts, 
osteoclasts derive from the mononuclear phagocytic system. This cell lineage is 
geared to operate in environments with low oxygen and pH content, circumstances 
normally found in inflammatory areas [23]. Thus, when oxygen tension and pH drop, 
these cells have enhanced proliferation and activity. This was shown in cultures of 
mononuclear cells of mice and humans, where number and size of osteoclasts were 
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stimulated when kept in hypoxic conditions also yielding higher resorption pits [12,29–
31].  
1.3. Bone Tissue repair: 
Bone has a strong intrinsic capacity for regeneration. Beginning during skeletal 
development in embryogenesis, this property is maintained in the continuous 
remodeling throughout adult life or as part of the repair process in response to injury 
[32,33]. Bone healing occurs through the classical healing cascade characterized by 
the inflammatory, repair and remodeling phases (Fig. 5). At the same time the injury 
site is progressively revascularized, which represents a crucial part of the regenerative 
process as stated above. The well-orchestrated interplay of biological events of bone 
induction and conduction that happen during bone regeneration involves many 
different cell types and molecular signaling pathways, happening in a well-defined 
temporal and spatial sequence. Fracture healing, as the most common form of bone 
regeneration, recapitulates both the direct and the indirect ossification routes [34]. This 
finely tuned balance influenced by fracture and location type, allows injuries and 
fractures of bone to heal without any scar formation, unlike many other organs.  
 
Figure 5: The fracture healing model consisting of the three response phases of inflammatory, repair and 
remodeling phase, accompanied by an increasing vascularization of the fracture site. Adapted from Pivonka et al.  
2012 [35]. 
 
 
 9 
 
1.3.1. The phases of bone healing:  
After bone fracture, ruptured blood vessels and vasoconstriction considerably lower 
blood flow to the injury site [36]. The molecular mechanisms activated by the hypoxic, 
post-traumatic environment trigger the release of pro-angiogenic factors such as 
vascular endothelial growth factor (VEGF) and other factors such as angiopoetin-1 and 
platelet-derived growth factor (PDGF). These factors lead to formation of new 
capillaries invading the fibrin clot and the developing newly-formed bone [37,38].  
However, the role of these factors can be multifunctional: VEGF for example, whose 
primary function is related to vascularization, is also implicated in the recruitment and 
differentiation of osteoprogenitor cells. Additionally, VEGF can regulate various 
osteoinductive factors (e.g. TGF-β1, insulin-like growth factors (IGF), fibroblast growth 
factor (FGF-2)), which in turn regulate its expression pattern. Degranulating platelets 
release PDGF at the injury site, which represents another crucial factor for fracture 
healing involved in both angiogenic and osteogenic processes. PDGF is chemotactic 
for progenitor cells, such as osteoblasts and is directly and indirectly pro-angiogenic 
(e.g. through upregulation of VEGF expression) [39].  
Progressive healing and concomitant changes in the mechanical forces within the 
newly formed bone entail secretion of matrix metalloproteinases (MMPs), which further 
stimulate vessel ingrowth and vascularization of the tissue [40]. As vascularization of 
the area further advances, normoxic conditions are restored and invading fibroblasts 
can start with remodeling the fracture hematoma , replacing it with highly vascularized 
granulation tissue [41,42].  
The anatomical location and mechanical factors influence the subsequent repair 
phase: when the two fractured fragments are compressed and thus interfragmentary 
movement is minimal, primary healing allows for direct deposition of mineralized 
matrix. In contrast, mechanically instable fractures heal through indirect healing 
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[32,41,43,44]. When the two surfaces are mechanically stable and compressed 
Haversian systems can bridge and later be infiltrated by osteoclasts, initiating the 
physiological process of bone remodeling [41,43,45]. Tunneling of the two segments 
by osteoclasts creates void space promptly colonized by blood vessels. Innate immune 
cells (e.g. Monocytes, macrophages) invading the area secern cytokines and 
chemotactic factors which further recruit local and systemic osteoprogenitors, 
fibroblasts and MSCs [46,47]. In contrast to direct deposition of mineralized matrix, 
indirect bone healing involves both intramembranous and endochondral ossification. 
The latter mechanism, also occurring during long bone development, involves bony 
transformation of a cartilaginous callus (described in previous chapters) and 
represents the central part of indirect bone healing.  
After the initial inflammatory phase, about 3 to 7 days after bone injury osteoblasts 
derived from the unharmed periosteum initiate intramembranous bone formation 
[48,49]. Once mineralized matrix has been directly deposited by periosteal progenitors, 
cartilaginous tissue formation begins 7-10 days after injury [32,50]. Cartilage tissue is 
formed as a result of low oxygen content in the injury area, which drives balance 
towards chondrogenic differentiation of progenitor cells [41,51,52]. Mechanical strain 
on the tissue hampers new vessel formation and the distance to the intact periosteal 
vascular network leads to insufficient blood supply to the area [53,54]. In the 
subsequent steps long bone development is resembled, comprising progenitor cell 
recruitment and condensation, proliferation, chondrogenic differentiation, 
mineralization, vascularization and remodeling. Initially in this process stromal cell-
derived factor-1 (SDF-1 ) plays a major role in progenitor cell recruitment [55,56]. 
SDF-1 is highly released during the acute phase of bone healing and efficiently 
mobilizes osteoprogenitor cells from the bone marrow which express CD44 and 
CXCR4, receptors of osteopontin and SDF-1, respectively [55]. FGF, Wnt, and BMP 
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pathways are other factors that drive the precisely orchestrated processes of 
endochondral ossification during bone healing. FGF and Wnt signaling synergistically 
control limb growth and inhibit chondrogenesis by maintaining progenitors in a 
proliferative and potential osteogenic  state [4,5]. On the other hand BMP and TGFβ 
signaling are responsible for chondrogenic differentiation of cartilage progenitors [6]. 
Following the endochondral ossification route, BMP triggers hypertrophy of 
chondrocytes through expression of Runt-related transcription factor 2 (Runx2), which 
together with the negative regulatory feedback loop between Indian Hedgehog (IHH) 
and Parathyroid Hormone-related Protein (PTHrP) represents the necessary steps of 
cartilage development towards bone [8,57,58]. These mechanisms are observed in the 
repair phase and the ensuing remodeling phase which can last years in the adult 
human and eventually bear a fully loadable bone [32,33,59]. The hypertrophic 
chondrocytes undergo apoptosis and release calcium, which increases the mechanical 
stability of the fracture site [53,60,61]. Low tissue strain favors blood vessel ingrowth 
in the injury area which supply the site with MSCs and monocytes [32].  While the 
former differentiate into osteoblasts, osteoclasts derived from the latter ones promote 
remodeling of deposited woven bone into lamellar bone. These two cell types tightly 
regulate each other by secretion of the cytokines MCSF, involved in osteoclast 
differentiation, and RANKL, responsible for osteoclast differentiation and the 
coordination of bone formation and bone resorption [62]. The diminishing strain on 
tissue in the injury site not only enhances vascularization but also allows 
intramembranous bone formation [44,63]. Together with a decrease of  most 
inflammatory cytokines, except IL-1, TNF-α and BMP-2, this phase occurs 4-6 weeks 
after fracture [51].  
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1.4. Large, complex bone defects and current treatment options:  
In the clinical routine the bone healing process can be aided by several interventional 
or conservative treatments. When treating bone fractures, surgeons can adapt and 
compress the two fragments to facilitate a rapid direct bone healing process. To 
stabilize the fracture, another key element for good bone healing as outlined in the 
section above, the treatment can foresee interventional procedures such as internal or 
external fixation or conservative application of a cast (or splint). Age, health condition 
of the patient, location and complexity of the fracture and concomitant injuries and 
diseases are determining factors for selecting the correct treatment strategy. If the 
bone fragments are well-aligned and stable, conservative treatment with a cast or a 
splint can be sufficient to allow good bone healing. However more complex or instable 
fractures can be treated by internal fixation, a long-established procedure which dates 
back to the mid nineteenth century [64]. The fixation can be performed with an 
intramedullary nail, which is inserted in the medullary cavity or by orthopedic plates 
and screws applied on the surface of the bone. During external fixation screws are 
fixed in the bone,  pierced through the skin and combined by plates outside the body 
[65,66].  
However, in large or highly complex bone defects the natural healing process often 
fails. This can be due to insufficient blood supply, extensive soft tissue injury around 
the bone, infection, neoplasm, radiotherapy, systemic disease or congenital disorders 
resulting in delayed union or non-union of bone.  
1.4.1. Treatment options in reconstructive surgery: 
For large defects which are unlikely to heal within a reasonable amount of time, plastic 
surgery has developed various reconstructive strategies: autologous grafts, including 
so called local flaps, regional flaps and free tissue transfer and procedures involving 
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allogeneic substitutes or synthetic materials count among the different options 
surgeons have [67]. The individual clinical scenario dictates the treatment algorithm to 
use, but vascular supply strongly influences successful accomplishment of every 
approach. Blood vessels guarantee survival of the transferred tissue by supplying 
required oxygen and nutrients, removing toxic waste products and by ensuring 
immunological protection of the tissue. Vascularization of tissue can occur 
spontaneously from the recipient site when the graft is not too large and the 
environmental quality of the defect site allows for it. Split thickness skin grafts in burn 
patients or cancellous bone grafts for bone reconstruction are examples where 
vascular ingrowth from the donor site is sufficient. In the first 48 hours simple oxygen 
diffusion and fluid imbibition enable graft survival of non-vascularized tissue after which 
neovascularization and/or inosculation take over. In neovascularization, new vessels 
sprout and invade the transferred tissue, while inosculation requires a preexisting 
vascular network of the graft, which connects to the recipient site and thus enables an 
almost instantaneous reperfusion [68,69]. Rapid perfusion is essential for large tissue 
transfers which cannot rely on vascularization from the injured site only. Vascular 
ingrowth would take too long to provide adequate perfusion to the entire graft, leading 
to complications such as necrosis and infection or even to loss of the graft. 
Circumventing this drawback by transferring the corresponding vessels together with 
the graft and microsurgically connecting them at the recipient site is the principle of the 
so-called “flap surgery”. In flap surgery the original blood vessel network of a tissue 
remains intact, thus, once connected to the recipient vessels, the graft does not depend 
on revascularization form the underlying recipient vascular bed. This makes it possible 
to transfer a significantly greater tissue volume than when non-vascularized grafts are 
transferred. Besides the great quantity of transferrable tissue, the great multiplicity of 
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tissue types in flaps make them an attractive solution: in one graft skin, muscle, nerve, 
fascia, and bone can be used to fill both large and multifactorial defects. 
With preserved original vascularization, the flap is immediately perfused after the inset 
into the defect. As a result, graft-survival and -engraftment as well as tolerance to 
infection and mechanical stress are improved compared to non-vascularized grafts. 
[70] The great versatility of flaps has allowed developing a large arsenal of grafting 
possibilities, which the treating surgeon can apply depending on several factors, such 
as viability of the surrounding tissue, size, shape and volume of the defect, desired 
biomechanical and biological characteristics of the graft, possible complications at the 
donor site, costs and ethical considerations. Together with these grafts, substitute 
materials are used, which can be either synthetic, biologically based, tissue-
engineered or a combination thereof [67,71]. 
2. Enhancement of bone regeneration 
2.1. Engineered, vascularized bone grafts 
As elaborate as aforementioned reconstructive techniques are, they all bear their 
bottlenecks. As many of them rely on autologous tissue, limited availability and donor 
site morbidity represent major hurdles, together with the fact that often they are not 
easily moldable to exactly fit in the defect site. In order to overcome these shortcomings 
tissue engineering has tried to develop alternative strategies for bone defects. Long-
term survival and function of a bone graft highly depends on its vascularization, 
supplying the indispensable oxygen and glucose when transplanted [72]. Given the 
fact that new vessels grow at approx. 5 µm/h and oxygen has a limited diffusion 
distance, a vascular network is mandatory to avoid necrosis of large grafts  [73,74]. 
This vascular network can either be reestablished from scratch by rapidly ingrowing 
vessels from the recipient site, as it happens in angiogenesis, or by inosculation, where 
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a pre-existing microvascular tree in the donor tissue connects with the recipient vessels 
[75,76]. Many approaches aimed at enhancing angiogenesis by altering the chemistry 
of the biomaterial or bioactivating their scaffold by incorporation of proteins [69,77–84] 
Others have tried to exploit the process of inosculation due to the almost instantaneous 
perfusion of the tissue after connection of the vessels. This upcoming concept in 
engineering bone grafts is intriguing because it allows high engraftment rates in large 
defects and in cases where the recipient environment has been damaged (e.g. 
infection, metabolic diseases, radiation etc.) [69,85–87]. In order to be endowed with 
a microvascular network available for inosculation, the to-be graft needs to be 
prefabricated, a procedure initially established in plastic and reconstructive surgery. 
Prefabrication consists in implementing an axial vascular pedicle in a formerly not 
axially perfused tissue. Neovascularization, driven by the inserted pedicle, generates 
a complete vascular network which supplies the flap. Eventually, the well 
revascularized tissue can be freely transplanted with a pedicle [88–90]. This concept 
has led to several strategies to prevascularize tissue in vitro or in vivo. In vitro cultures 
and co-cultures apply distinct cell types alone or together to achieve prevascularization 
[91–96]. Together with the cells, tissue engineering has tried to recreate the highly 
sensitive balance of available nutrients, cytokines, oxygen concentration, pH, ionic and 
electrical potential and mechanical stimulation in artificial settings [97]. Inability to 
resemble these extremely complex interactions has urged tissue engineers to avail 
themselves of the organism as a natural bioreactor, exploiting the body’s own 
regenerative capacity to generate vascularized bone grafts [97–101]. The basic 
elements of bone, namely osteogenic cells, an osteoconductive scaffold and 
osteoinductive proteins were combined within the organism to recapitulate 
skeletogenesis [101]. Cells, biomaterials and growth factors, representing the classical 
triad of tissue engineering, were tested in many different combinations and locations 
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applying the same underlying principle of the in vivo bioreactor. Developments in this 
field have led to the most notorious case which gave the engineering community a 
strong momentum. In the clinical case described by Warnke in 2004 a bone graft was 
prefabricated ectopically by prevascularization of a titanium cage filled with bovine 
bone ECM, BMP-7 and the patients BMSC [100]. After the bone graft was successfully 
transplanted to the patient’s mandibular defect as a composite muscle-bone graft, the 
patient died one year and three months later due to unrelated circumstances. However, 
besides the great surgical success and research breakthrough, the concept was never 
broadly applied in surgical practice due to unmet requirements to the graft, such as an 
non-resorbable titanium cage and heterogeneous distribution of mineralized tissue 
within the graft [102]. Nevertheless this study has demonstrated the great potential of 
translating tissue engineered concepts to the clinical practice, by ectopically 
engineering prefabricated composite grafts. 
2.2. Strategies of vascularization 
Using the body as an in vivo bioreactor by implanting a scaffolding material in an easily 
accessible area of the body represents a highly effective prevascularization strategy 
[103]. The strong angiogenic response drives random ingrowth of newly developing 
vessels in the tissue and generates a fully functional microvascular tree which allows 
the graft to be transplanted and the connect to vessels at the defect site by inosculation 
[75,104]. To generate a prevascularized tissue, several techniques have been 
developed. They can be categorized mainly in the arteriovenous (AV) loop - and the 
arteriovenous (AV) bundle technique (Fig. 6). 
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Figure 6: The arteriovenous loop (a) and the arteriovenous bundle (b) represent the most prominent strategies to 
vascularize tissue. In the AV loop an artery (A) is microsurgically anastomosed to a vein (V) by an interpositional 
graft (I). C represents the chamber in which the loop is studied. In the AV bundle an artery (A) and a vein (V) are 
ligated terminally (TL) to form a vessel bundle, without microsurgical anastomosis of the lumen.  The bundle is then 
inserted into the desired tissue structure, e.g. in bone segments, where capillaries and fibroblasts proliferate and 
provided osteoclasts and osteoblasts take part in bone remodeling. Adapted from Polykandriotis et al. 2012 [105] 
and from Tanaka et al. 2003 [106]. 
2.2.1. The arteriovenous loop: 
Erol and Sira demonstrated already in 1980 that by inserting an arteriovenous loop, 
namely an artery connected to a vein by an interpositional vein graft (Fig. 6a), between 
two dermal layers a vascular bed was created by spontaneous sprouting of vessels 
[107]. Inserting such a arteriovenous fistula proved to be a potent method of 
vascularization which did not only allowed upscaling of the graft but also generating a 
composite graft made up of multiple tissue types. Further proof for the high potency of 
the AV loop was provided twenty years later, when it was shown that an AV loop was 
able to revascularize a hollow plastic chamber devoid of a specific extracellular matrix. 
In a staged manner, the plastic chamber was initially filled with coagulated 
inflammatory exudate and granulation tissue, later with scar tissue which remodeled 
into mature dense connective tissue after 12 weeks [108]. This property of de-novo 
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tissue formation opened interesting opportunities, since tissue could be transferred 
without having the major drawback of tissue loss at harvesting site. Contingent on the 
tissue requirements at the defect site, donor site morbidity could be avoided completely 
[109]. Over time, different materials and extracellular matrices have been investigated 
in the context of AV loops, such as fibrin gel or matrigel [110]. These studies evidenced 
that a limiting factor for vascularization was the integration capability of the newly 
forming vessels with the supporting material. The better the integration could take 
place, the higher the vascularization was.  
 
2.2.2. The arteriovenous bundle: 
In contrast to the loop technique described in the paragraph above, the arteriovenous 
bundle consists in ligation of an artery and a vein at their ends (Fig. 6b). The AV bundle 
plays a major clinical role, e.g. when muscle flaps are harvested together with their 
vessels, which are terminally ligated [88,111]. The high efficiency of this technique in 
terms of tissue regeneration and vascularization was recognized already 4 decades 
ago, almost simultaneously to the studies performed on the AV loop [112]. This allowed 
its application in challenging clinical scenarios, such as osteonecrosis of the bone, by 
inducing bon regeneration in isolated bone segments, necrotized bone, and bone 
allografts. When comparing the bundle to singularly transplanted vessels or 
arteriovenous shunts, such as the loop, it was demonstrated that both techniques were 
comparable in revascularizing tissues [106]. New vessels, sprouting from the vein, 
were able to efficiently revascularize tissue in the same manner. However, the tissue 
generated by the AV bundle had already undergone extensive remodeling and 
reorganization after one month, whereas the tissue of the AV loop was still primordially 
organized. This increased regenerative capacity of the AV bundle is attributable to an 
underlying mechanism originating in the close surrounding of the vessels. The 
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sheathing tissue transplanted together with the bundle itself not only contains 
connecting capillaries and proliferating fibroblasts, but importantly also progenitors of 
any kind. In the case of bone, progenitors of osteoblasts and osteoclasts, residing 
therein, can initiate new bone formation and enhance resorption of necrotic bone. 
Eventually this means that the recipient bone, transplanted together with the bundle 
actively takes part of the remodeling bone. This knowledge, showing that the AV 
bundle is able to both effectively vascularize large tissues and to enhance bone tissue 
remodeling opened the possibilities apply this method to challenging clinical scenarios 
such as large and complex bone defects [112]. 
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3. Aims of the Thesis: 
 
3.1. General aims of the thesis: 
Based on the concepts described in the introductive chapter, the goal of my thesis is 
to generate a vascularized bone graft surrogate for large and complex bone defects. 
Stepwise, the challenges of such a bone graft were addressed: I aimed at developing 
an animal model to study large, complex bone defects and engineering an axially 
vascularized bone graft substitute, able to revascularize and induce efficient bone 
formation in this model (Chapter II). Secondly, I wanted to develop an appropriate 
imaging strategy thereof (Chapter III). Extensive review of the literature in chapter VI, 
led to development of a strategy to improve osteogenicity of the graft. Materials that in 
vivo can undergo robust bone formation processes, i.e. endochondral ossification, can 
be applied as off-the-shelf materials (Chapter IV) and finally integrating these concepts 
in the initially developed model (Chapter V).  
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3.2. Specific Aims of the thesis:  
Chapter II “Engineered, axially-vascularized osteogenic grafts from human adipose-
derived cells to treat avascular necrosis of bone in a rat model.” 
This chapter aims to develop an animal model suitable to study large bone defects and 
to generate an osteogenic vascularized graft. The hypothesis is that such a graft would 
be potent enough to revascularize and revitalize the entire devitalized bone block and 
generate new bone. Specifically, we assessed whether addition of SVF cells to the 
vascularized graft could create a favorable immunological response, enhance 
vasculogenesis in the area of simulated AVN, and improve bone deposition and 
resorption in the graft. 
Chapter III “Contrast-Enhanced Microtomographic Characterization of Vessels in 
Native Bone and Engineered Vascularized Grafts Using Ink-Gelatin Perfusion and 
Phosphotungstic Acid.” 
In this chapter the aim was to develop an imaging technique for vascularized bones 
(e.g., rat femur and tibia). In particular, we investigated the reliability of the 𝜇CT-based 
analysis of vessels contrasted with ink-gelatin/PTA and compared it to the standard 
histological assessment. Finally, we aimed to demonstrate the application of this 
method on 
simple engineered grafts consisting of vascularized porous hydroxyapatite, adapted 
from an avascular necrosis model used in rats. 
Chapter IV “Fat-derived stromal vascular fraction cells enhance the bone forming 
capacity of devitalized engineered hypertrophic cartilage matrix.” 
This chapter investigates the applicability of hypertrophic cartilage as off-the-shelf 
material for bone tissue replacement. To address the limitations of devitalized 
hypertrophic cartilage chips (HCC), which forfeits efficacy of bone formation by the 
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devitalization process, we tested the possibility to reactivate HCC with stromal vascular 
fraction (SVF) cells. We hypothesize that the mesenchymal, endothelial and 
osteoclastic progenitors, present in the SVF, can reactivate the HCC and thus lead to 
better bone formation.  
Chapter V “Prefabrication of a large pedicled bone graft by engineering the germ for 
de novo vascularization and osteoinduction” 
The aim of this study was to engineer an axially vascularized bone graft based on a 
developmentally inspired extracellular matrix. The hypothesis is that an engineered 
and devitalized cartilage matrix, combined with an AV bundle, is able to provide a germ 
for osteoinduction and vascularization.  
Chapter VI “Delivery of cellular factors to regulate bone healing” 
Bone tissue has a strong intrinsic regenerative capacity, thanks to a delicate and 
complex interplay of cellular and molecular processes, which tightly involve the 
immune system. In this chapter I review different approaches based on the delivery of 
regenerative cues produced by cells but in cell-free, possibly off-the-shelf 
configurations which could enhance bone replacement strategies.  
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Prefabrication of a large pedicled bone graft by engineering the germ for de novo 
vascularization and osteoinduction.  
Haumer A & Epple C, Ismail T, Lunger A, Scherberich A, Schaefer DJ, Martin I  
Abstract 
Large and complex bone defects represent challenging clinical scenarios. Autologous 
vascularized bone is typically used for reconstruction, but entails bottlenecks such as limited 
availability, donor site morbidity and restricted ability to be shaped into the desired form. Here, 
we thus aimed at ectopically prefabricating a pedicled bone graft surrogate.  
A form-stable outer shell of devitalized bone was used to define a space which was filled with 
bone-inducing engineered hypertrophic cartilage, in the form of vital or devitalized pellets, in 
combination or not with progenitor cells from the stromal vascular fraction (SVF) of adipose 
tissue. Vascularization of the space was targeted through axial insertion of an arterio-venous 
(AV) bundle.   Constructs were subcutaneously implanted in nude rats and assessed after 12 
weeks for bone formation and vascularization, using histological and microtomography 
imaging techniques. 
Retrieved constructs were efficiently vascularized in all conditions, with vessels sprouting from 
the AV bundle and reaching a higher density and larger diameter in the axially central volume. 
Bone tissue was formed through remodeling of hypertrophic cartilage (60%-75% of the 
implanted pellets), with no significant difference among experimental groups but in tight 
correlation with de novo vascularization. 
Our study demonstrates feasibility to prefabricate large, pedicled, form-stable bone grafts. The 
combination of an AV bundle with engineered hypertrophic cartilage provided a germ for the 
coupled processes of vascularization and bone formation. The demonstrated osteoinductive 
properties of devitalized hypertrophic cartilage offer the opportunity of implementing the 
proposed regenerative surgery strategy through off-the-shelf materials.  
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Introduction 
Large and complex bone defects represent challenging clinical scenarios. As diverse the 
pathogenesis and resulting clinical need is, so are its treatment strategies. The most effective 
standard of treatment for complex bone defects, for example in the maxillo-facial region, relies 
on the use of autologous vascularized bone grafts (e.g., pedicled fibula). This is associated 
with several bottlenecks, such as limited availability and significant donor site morbidity. 
Furthermore, shaping of complex, three-dimensional structures with available autologous bone 
can be cosmetically and functionally insufficient with restrained functional rehabilitation. An 
engineered osteogenic material, combined with a vascular bundle would represent an 
attractive alternative to develop a pedicled bone graft surrogate. In this regard arteriovenous 
fistulas have proved to be efficient in neovascularization of tissues for the past 40 years and it 
has been demonstrated that the performance of arteriovenous (AV) bundles is superior to AV-
loops in terms of tissue remodeling and regeneration, entailing less complications [1–5]. 
In a recently established rat model, we demonstrated that stromal vascular fraction (SVF) cell-
seeded hydroxyapatite scaffold, combined with a vascular AV bundle, efficiently vascularized 
necrotic bone and formed bone tissue de novo by direct ossification [6]. However, the 
procedure required culturing of the SVF cells in osteogenic medium for 5 days prior to 
implantation and newly formed bone ossicles were found in limited amounts and restricted 
regions.  
In the past, recapitulating the endochondral route of ossification has proved to be a robust 
strategy for bone formation in ectopic models as well as in orthotopic non-union models [7–
11]. The endochondral route of ossification can be recapitulated by generation of hypertrophic 
cartilage templates in vitro which embed the biological signals for the remodeling into a 
complete bone organ when implanted in vivo. Recently, we demonstrated that these 
hypertrophic cartilage templates can form bone ectopically and orthotopically after 
devitalization and ‘reactivation’ by stromal vascular (SVF) fraction cells [12]. Using multiple 
small modules - engineered & devitalized hypertrophic cartilage chips - would allow for 
reconstruction of complex, three-dimensional defects. 
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The aim of this study was to prefabricate an engineered, vascularized, pedicled bone graft 
substitute in an in vivo rodent model. The concept is based on following three pillars: a form-
stable outer shelf consisting of devitalized cancellous bone (Tutobone©), which is shapeable 
to specific needs and an inner core of hypertrophic cartilage, able to undergo bone formation 
in vivo. An AV bundle was axially implemented to provide a strong and reliable vascularization 
of the graft, as well as the pedicle for anastomosis to the recipient site.  
Methods 
Micromass culture and devitalization 
Human bone marrow derived stromal cells (hBMSCs) from three donors (all male, 33.3 ± 11.7 
years) were expanded as monolayers for two to four passages as previously described [13]. 
hBMSCs were detached and distributed in 1.5 ml screw cap Eppendorf tubes with 0.5x103 
cells per tube and centrifuged at 300g for 5 minutes. The resulting micromass pellets were 
then cultured in serum-free medium (Dulbecco’s modified Eagle’s medium, 1.25 mg/ml human 
serum albumin, 10 mM HEPES, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml 
streptomycin, 0.29 mg/ml glutamate, and ITS-A [10 mg/ml insulin, 5.5 mg/ml transferrin, 5 
ng/ml selenium, 0.5 mg/ml bovine serum albumin]; all from Invitrogen), supplemented with 10 
ng/ml transforming growth factor-b3 (R&DSystems), 10-7 M dexamethasone, and 0.1 mM 
ascorbic acid 2-phosphate (Sigma-Aldrich, St. Louis, MO, USA, 
https://www.sigmaaldrich.com) (chondrogenic medium). After 3 weeks of chondrogenic 
differentiation the resulting cartilaginous pellets were further cultured in hypertrophic medium 
(serum-free medium with 50 nM thyroxine, 10 mM b-glycerophosphate, 10-8 M 
dexamethasone, 0.1 mM ascorbic acid 2-phosphate, (Sigma-Aldrich) for 2 weeks as previously 
described with medium changes twice weekly [12]. A part of the resulting pellets were 
devitalized by three cycles of freezing (-196°C for 10 minutes) and thawing (37°C for 10 
minutes) and a final wash with deionized water. All fluids were removed and pellets stored at 
-80°C until further use (devitalized pellets conditions).  
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SVF isolation 
SVF cells were isolated from two liposuction and one excision fat samples from 3 donors (28.3 
± 3.7 years, two females and one male). The fractionated adipose tissue was incubated with 
0.15% collagenase type 2 solution (Worhtington-Biochem.com, Ref: LS004176, 345 u/mg dw) 
for 60 minutes, centrifuged at 300g for 10 minutes and the supernatants discarded. Cells were 
washed with complete medium to deactivate the collagenase, filtered through a sterilized tea 
strainer and a 100 µm mesh filter to remove undissolved tissue debris, and finally counted in 
a Neubauer counting chamber using crystal violet. The isolated SVF cells were then frozen in 
medium consisting of fetal bovine serum and 10% dimethyl sulfoxide and kept in the gaseous 
phase of liquid nitrogen until construct manufacturing.  
Grafts manufacturing 
The constructs were generated as described in Fig 1 A. Fibrinogen (Fibrinkleber SD TIM3, 
VNK4J002) and thrombin (SD TIM5 500 IE/ml, VNF4H023, both Baxter AG) were separately 
dissolved in sterile water, 40 mM of calcium chloride dihydrate (Fluka, now Sigma-Aldrich Ref. 
21102) added to the thrombin and both solutions frozen at -20°C for later use. 40 hypertrophic 
cartilage pellets were resuspended in 600 μL of fibrin gel (1:2 thrombin:fibrinogen). For the 
devitalized group with SVF cells, 12x106 SVF cells were added to each construct. The 
constructs were inserted in a hollow cylinder of processed bovine cancellous bone (Tutobone, 
Tutogen Medical, Neunkirchen, Germany), provided with a 1.5 mm drill hole at the base to 
allow later insertion of the arteriovenous bundle. The whole graft was wrapped in 
semipermeable anorganic-based silicone membrane to prevent ingrowth of host cells from the 
outside (Biobrane, UDL Laboratories Inc., Rockford, IL, USA) [14] . An 18G peripheral venous 
catheter with needle (B. Braun Melsungen AG, Melsungen, Germany) was then used to pierce 
through the packed construct to allow for an easy introduction of the vascular bundle into the 
construct [6].  
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Implantation  
For in vivo implantation, 18 young athymic nude rats (RH-Foxn1rnu, Envigo, Venray, The 
Netherlands) were operated with permission of the Federal Veterinary Office (permit BS 2598). 
Animals were held in groups of three with unrestricted access to food and water. Before 
surgery, 0.05 mg/kg buprenorphine (Temgesic, Reckitt Benckiser, Wallisellen, Switzerland) 
was injected subcutaneously for analgesia. Then inhalation anesthesia was induced and 
maintained with 1.5-3 % Isofluran (Baxter, Volketswil, Switzerland) in 1 l/min oxygen. The rats 
were placed in a supine position on an electrically heated mat, the operation area disinfected 
and a sterile operating field established. An incision of approximately 15 mm was made along 
the left groin and the superficial inferior epigastric artery and vein dissected free with help of 
an operation microscope, making sure to leave a small amount of connective tissue in place 
around the bundle. After distal ligation and transection of the bundle, the ligature thread was 
used to gently pull the vascular bundle through the prepared construct, using the peripheral 
venous catheter as a guide and removing it in the process. A subcutaneous pouch was then 
created by blunt dissection and the pedicled construct inserted carefully. The wound was then 
closed by layered subdermal and intradermal suturing with absorbable material (5-0 Monocryl, 
Ethicon, US) and the animal returned to the cage, closely monitored and treated with analgesia 
according to the veterinary study guidelines.  
Construct harvesting  
After 12 weeks, deep anesthesia of the animals was induced by intraperitoneal injection of 
mg/kg ketamine (Ketasol 100, Dr. E. Graeub AG, Switzerland) and 10 mg/kg xylazine (Xylasol, 
Dr. E. Graeub AG). Additionally an inhalation anesthesia with 1.5.-3 % Isoflurane in 1 l/min 
oxygen was used. The animals were again placed in a supine position and through a median 
laparotomy the abdominal aorta was exposed and dissected free from the inferior vena cava. 
The aorta was then cannulated with a 23G butterfly cannula (BD, Heidelberg, Germany) and 
a heparinized saline solution (100 IU/ml, 0.9 % NaCl, B. Braun AG, Switzerland), followed by 
a dark-blue contrasting agent (5% w/v Gelatine-Gold, Carl Roth GmbH, Karlsruhe, Germany; 
50% v/v Indian Ink, Lefranc & Bourgeois, Le Mans, France; 4% w/v D-Mannitol, Carl Roth 
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GmbH; distilled water) was injected until the skin of the lower extremities turned black, followed 
by immediate euthanasia of the rat by exsanguination. The cadavers were refrigerated at 4°C 
overnight to allow for polymerization of the contrast agent-containing gelatin. The constructs 
were then cautiously dissected free from the surrounding tissue, the state of the vascular 
bundle macroscopically assessed and the constructs including the bundle transferred to a 
solution of 1% PFA in distilled water for 24 hours, followed by immersion in PBS and 
preparation for microtomography. 
Histology 
All histological samples were embedded in paraffin using a TES Valida embedding station and 
sectioned using a Microm HM 340E Microtome. 
To check for successful differentiation into hypertrophic cartilage of the expanded hBMSCs, 6 
randomly picked pellets were processed histologically and stained with Safranin-O (Sigma Ref. 
84120), fast green FCF (Sigma Ref. F-7252) and immunohistochemically stained with collagen 
II (Abcam ab49945) and collagen X (Abcam ab185430) antibodies. For immunological 
stainings, a goat anti-mouse IgG/ Biotin antibody (Dako E 0433) was used as a secondary 
antibody and the staining developed with the Vectastain ABC / AP Kit (Linaris AK-5000) and 
Vector Red AP Substrate kit 1 + Levamisole (Linaris SK-5100) and then counterstained with 
hematoxylin. 
After tomography, constructs were sectioned into a proximal and distal half, processed, 
embedded in paraffin and sections cut with 5-10 µm slice thickness. To achieve a close 
histological representation of the constructs, slides were made on three levels per half 
construct to cover 290 µm per level and 670 µm in total. Hematoxylin-eosin (HE Papanicolaou 
J.T.BAKER, Eosin 2% + Erythrosin B 1%; from Biosystems: Hematoxylin 38-7025-00/38-73, 
Eosin 84-0012-00 Erythrosin 84-0013-00) and Masson’s trichrome staining (Réactifs RAL, 
Martillac, France) were performed to assess tissue morphology, bone formation and 
maturation. ALU-sequence staining (Zytovision GmbH, Bremerhaven, Germany) for cells of 
human origin and immunohistochemistry for human CD34+ endothelial cells (Millipore CBL 
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496 from DAKO) were performed to investigate their presence and contribution in SVF-seeded 
constructs [6]. 
Image acquisition 
Single images for illustration purposes were taken with Olympus BX61, BX63 and IX83 
microscopes. Serial pictures for quantification were taken with a Nikon up right Ni, connected 
to a Prior robot and with 4x and 10x objectives.  
Quantification 
Images were analyzed with Olympus cellSens Dimension 1.15 (Build 14760) and Nikon NIS-
Elements AR 4.51 (build 1143) software. For vessel quantification, structures were counted on 
pictures taken with 10x magnification. Vessels were defined by endothelial cell lining, a well-
defined lumen and the presence of either red blood cells or contrasting agent (Indian ink) inside 
the lumen. Counting was done by two independent observers in blinded samples. Bony regions 
were identified by the presence of densely organized, homogenous, cell-poor areas with or 
without bone marrow. These regions, total pellet area and the inside area of the Tutobone 
cylinder were selected manually and the area provided by the imaging software. Percentages 
of remodeled area to total pellet area and of pellet area to total construct area were calculated 
to account for the distribution of the pellets in the constructs. 
Microtomography 
For microtomography, constructs were placed in a 10-ml syringe barrel containing 1 ml of 
HistoGel (HG-4000-012, Thermo Fisher Scientific, 168 Third Avenue, Waltham, MA USA 
02451) to conserve and stabilize the sample during transport and scanning. All samples were 
scanned twice: first without any contrast agent (for imaging of mineralization/bone) and a 
second time after decalcification with a 15% w/v EDTA (Sigma-Aldrich) solution in distilled 
water at 37°C for one week and consecutive radio-dense contrasting of the vessels with 5% 
w/v phosphotungstic acid (Sigma-Aldrich) in distilled water at room temperature for 24 hours, 
to image the vascular bed, as previously described [15]. All samples were scanned at 360° 
using a tungsten x-ray source with a voltage of 70kV and a current of 260 µA (Nanotom M, 
 72 
 
GE, USA). To reduce beam hardening artifacts, a 0.5 mm aluminum filter was applied. 
Volumes were reconstructed with 8.5-12 µm voxel size using the manufacturer’s software and 
analyzed with VGStudio Max version 2.2 (Volume Graphics, Heidelberg, Germany). 
Bone/ mineralization assessment  
Total mineralization of the implanted construct was assessed by creating a cylindrical region 
of interest (ROI) of the Tutobone’s inside and using VGStudio Max Volume analysis tool. Gray 
values thresholds were chosen with help of the histogram and visual control to eliminate all 
non-dense material and background signal. Voxels of the selected gray values were counted 
by the software and corresponding volumes automatically calculated, giving the total 
mineralized volume of the constructs. Absolute bone volume was quantified by matching the 
µCT data on mineralized tissue with histologically-proven bone tissue. The number and volume 
of all pellets was counted and measured manually by creating ROIs for each pellet. The 
morphology of the pellets was assessed for the presence of bone-like structures like vascular 
ingrowth perforation of the mineralized shell, trabeculae inside the pellets, fused pellets and 
round shaped osteoid deposits, and compared with corresponding histological sections. 
Number and volumes of pellets with signs of remodeling into bone were measured. 
Vascularization assessment 
Vascularization was assessed in reconstructed volumes of PTA-stained constructs with a 
focus on characterizing the AV-bundle and its branching vessels. The AV-bundle and 
branching vessels were identified by radiodensity, and the diameters and numbers measured 
or counted on transversal planes. Measurement of the largest vessel was performed on short 
and long axes on three levels: the proximal entry point of the bundle into the Tutobone, in the 
middle and at the distal end of the Tutobone just over the drill hole. Furthermore, the shortest 
and longest distance between remodeled pellets and the central vessel were measured. By 
superimposing µCT-datasets taken with and without phosphotungstic acid, it was possible to 
subtract the signal of the radio-dense pellets from the 3D-reconstruction to visualize selectively 
the PTA stained structures.  
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Statistical analysis 
All statistical analyses were performed using GraphPad Prism software (GraphPad Software, 
Inc., California, USA). Kruscal-Wallis test, Dunn’s multiple comparisons test and Spearman’s 
rank correlation coefficient were performed considering a p-value of <0.05 significant. Results 
are reported as mean ± standard deviation unless otherwise indicated.  
Results 
Successful in vitro cartilaginous differentiation and hypertrophy of the hBMSC micromass 
pellets was demonstrated by high glycosaminoglycan content (red in Saf-O staining) and 
positive immunohistochemical stainings for collagen II and X (Fig. 1 B). Vital and devitalized 
(with and without SVF) pellets were then inserted in the cancellous bone cylinder together with 
an AV bundle and implanted in nude rats (Fig. 1 A). All 18 implanted constructs (6 constructs 
containing vital pellets without SVF cells, 6 constructs containing devitalized pellets without 
SVF cells and 6 constructs containing devitalized pellets with SVF cells) were explanted after 
12 weeks in vivo. A visual inspection revealed signs of thrombosis in AV-bundles of four 
constructs (2 vital, 1 devitalized and 1 devitalized + SVF). These constructs showed signs of 
limited engraftment with fibrotic tissue and marked inflammatory response. Due to the surgery-
related technical failure, these 4 constructs were excluded from the study and not further 
analyzed.  
Bone assessment and quantification  
Bone tissue was formed in 3 out of the 4 constructs containing vital pellets and in 3 out of the 
5 constructs containing devitalized pellets, both in the presence and in absence of SVF cells 
(Fig. 2 A). H&E-stained sections demonstrated, beyond a dense collagen matrix, fused pellets 
and formation of bone marrow elements, indicating the maturation into trabecular bone (Fig. 2 
A). µCT imaging confirmed fusion of the pellets and voids in the mineralized structures, 
indicating ingrowing vessels, and osteoid tissue vascularization (Fig. 3 B). Bone tissue 
formation was not homogenous all over the implanted constructs, but only took place at a radial 
distance of 0.2-2.2 mm from the central vessel (on a maximal potential radius of 5 mm, Supp. 
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Fig. 1). In all construct types, bone formation was rather variable along the longitudinal axis, 
with a tendency for higher amounts of bone in the proximal half of the construct (Supp. Fig. 2). 
Quantification of the percentage of the average pellet area remodeled into bone tissue by 
histological morphometry revealed a stronger level of bone formation in constructs containing 
vital hypertrophic pellets (17.2 ± 9.7 %; Fig. 2 B) than in constructs containing devitalized 
pellets (2.8 ± 4.3 %) or devitalized pellets with SVF cells (1.5 ± 2.4 %). However, given the 
high variability of bone formation within the experimental groups (e.g. varying from 0 - 43 % in 
the vital pellets’ group) and the limited number of analyzed replicates, the difference in terms 
of bone formation was not statistically significant among the groups. All three conditions 
exhibited the same density of infiltrating CD68+ macrophages (Supp. Fig. 3). CD68+/CD163+, 
M2-like macrophages were significantly more frequent in the vital constructs, representing 40% 
of all macrophages. In constructs with devitalized pellets, M2-like macrophages were more 
abundant when SVF cells were added (29%), while only 6% of the invading macrophages were 
polarized towards an M2 phenotype when only devitalized pellets were implanted. 
Total mineralized volume was quantified by µCT. Thresholding for densities corresponding to 
mineralization, eliminating the signal due to soft tissue and background, was possible on the 
gray value histogram by visually controlling the selected voxels (Supp. Fig. 4).  Mineralization 
was not different among the three groups (12.8 ± 3.2 mm3, 11.8 ± 2.4 mm3 and 14.5 ± 3.8 mm3; 
Fig. 3 A). Bone volume, calculated by adjusting the imaging threshold to the histologically 
proven bone, was maximal in the control group with 5.1 ± 2.2 mm3, whereas the devitalized 
pellets only generated 1.2 ± 0.7 mm3 of bone tissue and the devitalized pellets + SVF 1.4 ± 0.7 
mm3 (Fig. 3 C). However, differences were not statistically significant. The average pellet 
volume transformed into bone was also evaluated by µCT and was consistent with 
histomorphometry data, with 24.6 ± 11.7 % in the vital group, 3.9 ± 2.7 % in the devitalized 
group and 6.1 ± 3.4 % in the devitalized + SVF group, but again with no significant difference 
among the groups (Fig. 3 D). Staining for human ALU-sequences evidenced the presence of 
human cells inside the pellets (Supp. Fig. 5) after 12 weeks in vivo, documenting the survival 
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of a fraction of the implanted SVF cells, with a possible contribution in cartilage matrix 
remodeling and bone formation. 
Vascularization analysis 
We then assessed the vascularization inside the bone grafts after 12 weeks in vivo implantation 
time. Phosphotungstic acid-contrast enhanced µCT showed that in all constructs included for 
analysis, the graft was fully vascularized with small and intermediate sized vessels arising from 
the central arteriovenous bundle, spreading towards the surrounding devitalized bone (Fig. 4 
A). Histological analysis confirmed the high level of vascularization in every experimental 
condition, as documented by the uniform distribution of vascular lumens filled by Indian ink 
(black arrows in Fig. 4 B) around the vascular bundle and in vicinity of the devitalized pellets. 
The radial distribution of vessels showed a statistically significant difference in all groups 
between the central (0-2.5 mm) and the peripheral (2.5-5 mm) half of the construct. In 
particular, the central part close to the main bundle was better vascularized with an up to 5-
fold higher vessel density than the peripheral part (Supp. Fig. 6). 
Quantification of vessels’ diameter showed no significant difference between the experimental 
groups, although the mean diameter of central vessels in the constructs containing living 
pellets was in average twice larger (468 ± 111 µm) than in the devitalized (243 ± 68 µm) or 
devitalized pellets + SVF (190 ± 70 µm) groups (Fig. 4 C). The number of vessels branching 
from the central bundle also did not statistically differ among groups (Fig. 4 D).  
Correlation of vascularization and bone formation  
Despite no statistical difference could be evidenced among the groups in either diameter of 
central vessel or density of vascular network, a correlation could be established between 
vascularization and bone formation. The size of the central vessel diameter was positively 
correlated to an increased bone formation, with a linear correlation of r2=0.74 (Fig. 5 A).  An 
even higher positive linear correlation of r2=0.77 could be demonstrated between the vascular 
density and the newly formed bone volume (Fig. 5 B).  
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Discussion 
This study demonstrates that by combining engineered hypertrophic cartilage with an AV 
bundle within a form-stable outer shell it is possible to prefabricate a vascularized bone graft 
with an inherent germ of osteoinduction and vascularization. The vessels sprouting from the 
AV bundle strongly influenced the bone forming capacity, underlined by the fact that in the 
peripheral areas where vascularization decreased, bone formation was not observed.  
The implementation of an axial AV bundle gave a thorough vascularization of the entire 
construct, indispensable for large bone grafts [16–18]. Also, the pedicle of this prefabricated 
bone graft surrogate offers the advantage that once anastomosed to the recipient vessels, it is 
entirely perfused through the already existing vascular network. In clinical translation of large 
tissue engineered bone grafts this has been a major limiting factor [19]. The high vessel density 
in the area surrounding the central AV bundle, together with the high number of branches 
arising from the main trunk, indicate an efficient vascularization process. In mature individuals, 
luminal vessel sprouting is believed to be the major process during angiogenesis and in AV 
bundles it typically occurs from the central vein  [5,20]. The process underlying angiogenic 
luminal sprouting begins with promoting factors urging detachment of pericytes and endothelial 
cells [21]. The initial hypoxic and inflammatory environment within our constructs, as well as 
VEGF present in the hypertrophic cartilage, are strong promoters for the detached, reactive 
endothelial cells. Proteases further liberate proangiogenic factors from the ECM such as VEGF 
and FGF and endothelial sprouting is initiated by migrating and proliferating endothelial cells 
[22]. To avoid aberrant, random endothelial cell migration and ensure the generation of a 
functional neo-lumen, one endothelial cell is selected to become a tip cell by factors such as 
VEGF receptors, neuropilins (NRPs) and the NOTCH ligands DLL4 and JAGGED1 [23]. 
Endothelial cells in the vicinity of the tip cell are stimulated by NOTCH, Notch-regulated ankyrin 
repeat protein (NRARP), WNTs, placental growth factor (PlGF) and FGFs, to become 
elongated stalk cells and finally form the lumen, mediated by VE-cadherin, CD34, sialomucins, 
VEGF and hedgehog [24]. In our study, we could observe a limit in efficiency of vascularization 
at a radial distance of 2.5 mm from the AV bundle. The vessel density in the peripheral area 
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beyond this point was significantly lower than in the central part. A possible explanation for this 
decrease in vascularization could lie in the nature of tip cells. These cells are equipped with 
filopodia which sense environmental cues to guide them, such as ephrins and semaphorins 
[25]. In absence of these factors in the peripheral zone of our construct, tip cells become 
quiescent and stabilize. Ones stabilized, endothelial cells are covered by pericytes and a basal 
membrane is deposited, marking the end of the sprouting process.  
Besides a solid vascularization, we generated a germ of bone formation within our constructs 
by using engineered hypertrophic cartilage. It has been shown that cartilaginous tissues 
engineered from hBMSC can act as a template for bone formation derived from the synergy of 
donor and host cells in both ectopic and orthotopic animal models [7,10]. Moreover, freeze and 
thaw (F&T) devitalized hypertrophic cartilage pellets were so far shown to undergo 
endochondral ossification upon in vivo implantation if reactivated by addition of SVF cells [12]. 
In order for devitalized cartilaginous tissue to undergo ossification in vivo without the addition 
of external cells, it was reported that a devitalization method able to maintain important 
biological cues in the ECM is required [26]. It is noteworthy that in our constructs, hypertrophic 
cartilage pellets devitalized by F&T and thus with compromised composition of the ECM were 
still able to form bone, in a quantity which was not statistically significant inferior as compared 
to the vital ones. A possible explanation for this finding lies in the privileged environment 
created by the AV bundle. The surrounding tissue transplanted together with vessels, where 
capillaries and fibroblasts proliferate, may provide osteoclasts and osteoblasts which resorb 
avital bone and at the same time stimulate bone formation and bone remodeling.  
Often, this tissue remodeling is associated with specifically increased immunological cell 
subtypes, such as alternatively activated (pro-regenerative/M2-like) macrophages [27]. 
However, we could not observe any correlation between M2 polarization of invading 
macrophages and new bone formation. As previously observed, transplanted SVF cells are 
able to induce an M2 phenotype in macrophages [6]. In the constructs containing devitalized 
pellets they could revert absence of M2 macrophages, however this phenotype switch did not 
entail increased bone formation. This emphasizes the fact that to enhance a regenerative 
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process in bone tissue engineering a precise understanding of the role and dynamics of 
immunological cell populations is necessary [28,29] and the specific role of macrophagic 
populations, with phenotypes hardly categorized in artificial classes, is still elusive.  
In our generated bone graft, the functional AV bundle was sufficient to lead to bony remodeling 
of the implanted pellets, since addition of SVF cells could not enhance the bone quantity. In 
fact, what emerged to have the strongest influence on the bone forming capacity was 
vascularization of the construct. Central vessel diameter and vessel density tightly correlated 
to bone formation. This finding is consistent with the knowledge that increased vascularization 
of a tissue can increase its regenerative capacity, since vascularization is a “critical obstacle 
in engineering metabolically active tissues”, [30]. Not only does vascularization enhance 
regenerative capacity, it also plays a major role in bony transformation of a cartilaginous 
template. Two mechanisms are mainly responsible for this: Oxygen tension plays an important 
role in regulating chondrocyte behavior and regulates its hypertrophy and transformation into 
bone. The mostly avascular cartilage thrives under hypoxic conditions, while in the ossification 
front of developing bone, invading blood vessels increase the oxygen tension driving the 
equilibrium towards bone formation [31]. Secondly, vessels play an indirect role in the 
remodeling of the cartilaginous matrix to bone. Attracted by VEGF secreted from the 
hypertrophic chondrocytes, the invading vessels provide chondroclasts for the degradation of 
cartilage as well as osteoblasts and osteoclasts, responsible for the deposition and remodeling 
of true bone matrix [32].   
The here gained knowledge could inspire possible improvement to extend bone formation 
beyond the central zone. The observed decrease of vascularization, and thus vanishing of 
bone formation, could be explained by the high content of fibrin gel present. It is known that a 
material’s properties strongly influences the vascularization [33]. For example, pore structure 
and size of the hydroxyapatite scaffold used in Ismail et al.’s work was shown to be permissive 
for guided vascularization [6]. In fact, with the same axial AV bundle technique, bone formation 
was observed up to 4.5 mm. Thus, to increase vessel density beyond 2.5 mm from the central 
AV bundle, one could either increase the ratio of scaffolding material, i.e. pellet volume 
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(decreasing the amount of fibrin), or stimulate vessel formation by a growth factor-enhanced 
environment. Increasing the cartilage pellets number, which in our study was limited to 40 per 
construct, could enhance both vascular guidance and bone forming foci. In this regard, 
switching to a different in vitro culture method could provide the solution. It was demonstrated 
that hBMSC can undergo endochondral ossification when seeded on type I collagen sponges 
of variable sizes [13,35]. Seeding hBMSC on collagen sponges would allow generating larger 
pellets and thus facilitating production of large quantities of matrix, which would be then 
devitalized as possibly used as off-the-shelf filler material. 
Conclusion  
In this study we showed that an axially implemented central arteriovenous bundle plays a key 
role in the bone formation capacity of engineered hypertrophic cartilage. In challenging clinical 
scenarios, e.g. in the maxillo-facial region, the complexity of the defects often limit conventional 
reconstruction with autologous tissue. For these cases, our proposed approach could provide 
an alternative bone graft surrogate as a prefabricated, pedicled, large bone graft with a form-
stable, outer shell and an inner core containing a germ for bone and vascularization. While this 
inner core represents the biological backbone allowing physiological behavior of the graft, the 
outer shell can be adapted to the defect by 3D CAD-CAM techniques and thus fit the defect 
site exactly in size and shape.  
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Figure Legend: 
Figure 1: Constructs generation and in vitro differentiation of hBMSC pellets. Figure 1A shows 
how constructs were generated prior to implantation. Either vital or devitalized pellets were 
used within a fibrin gel together or not with SVF cells from human adipose tissue. Finally the 
pellet/fibrin mix was introduced in a hollow cylinder of devitalized cancellous bone together 
with an axially implemented AV bundle generated from the epigastric vessel sof a nude rat. 
The construct was the  inserted subcutaneously. Fig 1B shows Successful in vitro cartilaginous 
differentiation and hypertrophy of the hBMSC micromass pellets was demonstrated by high 
glycosaminoglycan content (red in Saf-O staining) and positive immunohistochemical stainings 
for collagen II and X. 
Figure 2: Bone formation in vivo. Figure 2 A demonstrates bone formation in all three 
conditions. H&E and Masson Trichrome stained sections demonstrated a dense collagen 
matrix, fused pellets and formation of bone marrow elements, indicating the maturation into 
trabecular bone Figure 2 B shows the percentage of pellet area transformed into bone after 12 
weeks in vivo. Vital pellets did not generate a significantly higher percentage of bone compared 
to devitalized and devitalized pellets with SVF cells. 
Figure 3: Assessment of mineralization and bone formation with uCT. A shows that mineralized 
volume was the same in all three groups. Bone volume in fig. 3B, assessed by adjusting uCT 
data with histologically proven bone, did also not show a statistical difference among the 
groups. Percentage of bone volume transformed into bone (3C) confirms the trend seen in the 
percentage of the pellet area transformed into bone calculated with histological means.  
Figure 4: Assessment of vascularization. Contrast enhanced uCT in figure 4A shows vessels 
spreading from the central AV bundle to the periphery of the constructs. Histological analysis 
confirmed the high level of vascularization in every experimental condition, as documented by 
the uniform distribution of vascular lumens filled by Indian ink (arrows). Although the mean 
diameter of central vessels in the constructs containing living pellets was in average twice 
larger than in the devitalized or devitalized pellets + SVF groups (Fig. 4 C). The number of 
 84 
 
vessels branching from the central bundle, shown in figure 4D also did not statistically differ 
among groups. 
Figure 5: Correlation between bone formation and vascularization. Figure 5 A shows a direct 
positive correlation (P=0.0002; r2=0.742) between the bone volume and the proximal vessel 
diameter. Figure 5 B shows a positive correlation (p< 0.0001; r2=0.77) between the vessel 
density and bone formation. A higher vessel density could also be evidenced in the radially 
central part of the construct compared to the periphery (p=0.0016). This tightly correlated with 
the pellet area transformed into bone which was strictly in the central part (Fig. 5D; p=0.0002) 
Supplementary figure 1: Bone formation along the transversal axis. Bone tissue formation was 
not homogenous all over the implanted constructs, but only took place at a radial distance of 
0.2-2.2 mm from the central vessel 
Supplementary figure 2: Bone formation along the longitudinal axis. Bone tended to be formed 
more in the proximal part of the construct. 
Supplementary figure 3: Polarization of invading macrophages. All three conditions exhibited 
the same density of infiltrating CD68+ macrophages (Supp. Fig. 3). CD68+/CD163+, M2-like 
macrophages were significantly more frequent in the vital constructs (Vital vs Devitalized: 
p=0.0049) representing 40% of all macrophages. In constructs with devitalized pellets, M2-like 
macrophages were more abundant when SVF cells were added (29%; Devitalized + SVF vs. 
Devitalized: p=0.04), while only 6% of the invading macrophages were polarized towards an 
M2 phenotype when only devitalized pellets were implanted. 
Supplementary figure 4: Thresholding for densities corresponding to mineralization, eliminating 
the signal due to soft tissue and background, was possible on the gray value histogram by 
visually controlling the selected voxels. 
Supplementary figure 5: Staining for human ALU-sequences evidenced the presence of 
human cells inside the pellets 
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 Delivery of cellular factors to regulate bone healing 
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5. Conclusion and perspectives:  
Infection, trauma, tumor and burn sequelae can lead to varying degrees of tissue 
damage, resulting in complex defects including muscle and bone. At the beginning of 
the previous century, such damage often resulted in amputation of a limb or organ, or 
even death of the patient. Two of the most important medical advances of the 20th 
century have made it possible to offer these patients a better option. First, autologous 
tissue grafting, where tissue is transferred from an unharmed part of the own body to 
the injury site, allowed to restore crucial body function and coverage. Secondly, defined 
body areas with constant, independent and reliable blood supply were discovered. This 
promoted clinical implementation of the grafting concept by providing a fast and 
efficient vascularization of the transferred tissue, which in turn made graft and flap 
surgery possible. Technological development in microsurgery from the 1960ies on, 
allowed to constantly refine and broaden the surgical options in reconstructive surgery. 
Despite many sophisticated techniques have been developed to repair tissue defects, 
grafting in reconstructive surgery almost entirely relies on native tissues. However, 
these tissues are limited in availability and in its suitability to match the defect site in 
size and shape. 
My thesis aimed at overcoming these shortcomings by developing a prefabricated, 
large, vascularized bone graft for the treatment of complex bone defects.  
In chapter II a vascularization method, suitable for prefabricating a large bone graft, 
was tested in a relevant animal model. The concept of prefabrication relies on the 
process of neovascularization of a tissue by introducing a vascular pedicle in a defined 
tissue segment, allowing for reimplantation of the tissue as free graft [113]. In order to 
observe bone formation in such a setting, living cells from the stromal vascular fraction 
(SVF) are required to be seeded on an osteoconductive ceramic material. In the third 
chapter a contrast-enhanced microtomographic imaging technique was developed to 
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critically assess vascularization and bone formation in this large-sized constructs, to 
provide a comprehensive overview by computed reconstruction of the data.  
The fourth chapter addresses the bone formation in the inner core of the graft. After 
extensively reviewing the literature, described in the last chapter, it became clear that 
extracellular matrix deposited by mesenchymal stromal/stem cells during an in-vitro 
phase could allow to deliver the physiological cocktail of signaling molecules required 
for the regeneration of bone tissue. Subsequent devitalization and transplantation of 
the tissue offers the highly attractive opportunity to exploit the regenerative potency of 
the ECM, but within a cell-free, off-the-shelf material. Based on their design, these 
materials harbor not only all the cyto- and chemokines necessary for recruitment and 
differentiation of progenitor cells, but also for activation and regulation of the immune 
response, able to promote regeneration. This knowledge allowed developing an 
engineered, devitalized matrix, which proved to be a robust bone formation strategy 
ectopically and orthotopically, when ‘activated’ by co-transplanted SVF cells.  
Finally, the fifth chapter demonstrates that combining an AV bundle and the 
engineered, avital matrix is sufficient to generate a germ of vascularization and bone, 
without the addition of a living cell compartment. Eventually, the potency of the AV 
bundle in promoting bony remodeling of the cartilage template was shown by a direct 
positive correlation of vascularization and bone formation. Together with a form-stable 
outer shell, which can be custom-shaped according to the patient’s needs, this 
prefabricated vascularized graft represents a real alternative bone graft surrogate.  
This innovative concept investigated in my thesis opens interesting opportunities for 
clinical translation, because it allows to combine the safety and reliability of 
conventional surgical approaches, such as free tissue transfer, with innovative 
materials and tissue engineering technologies.  
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In fact, feasibility and safety of this approach was tested in a one-patient clinical case. 
A young patient with a complex maxillary defect, originating from the removal of an 
aggressive, malignant tumor, was not eligible for reconstruction of the defect by 
conventional means. To offer the patient a reasonable long term solution, the concept 
described above was clinically translated in a two-step approach, involving ectopic 
prefabrication of the graft, followed by orthotopic transfer of the tissue to the defect 
zone. In the first step, the exact size and shape of the defect were calculated from 
tomographic data. Through CAD-CAM techniques, an exactly matching, three-
dimensional scaffolding material, made of devitalized cancellous bone, was generated. 
To provide a combined germ of vascularization and bone formation, an AV bundle was 
axially inserted in the material which was seeded with SVF cells, gained 
intraoperatively from the patient. The stromal and vascular progenitors contained in 
the freshly isolated SVF enhance the vascularization of the material through the AV-
bundle, in turn improving its engraftment following orthotopic transfer, as well as 
tolerance to infection. At the same time progenitor cells of the SVF cells require a 
molecular trigger to differentiate into functional osteoblasts, which was achieved by 
supplying low amounts of rhBMP-2 together with the SVF cells [114,115]. Accurate, 
longitudinal imaging allowed to assess the development and maturity of the tissue. The 
AV bundle, created from two thoracodorsal vessels, proved to be an efficient 
vascularization method also in this clinical setting. The large-sized graft of nearly 28 
cm3 was entirely vascularized within the first four weeks of ectopic implantation. At 
orthotopic transfer, the pedicle originating from the implemented AV bundle could be 
safely anastomosed to facial vessels by microsurgical means. The newly developing 
bone, assessed by CT and PET-CT scans to define structure and metabolism, showed 
increasing grades of maturity beginning from the 8th to the 12th week. With advancing 
metabolic activity within the bone graft, resorptive processes could also be observed. 
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Continuous imaging assessment made it possible to precisely surveil these processes 
and define the appropriate time point for graft transfer. Based on this, after 8 months 
of ectopic prefabrication, the bone graft could be harvested and transferred to the 
maxillary defect site.  
This successful translation of the concept from the bench to the bedside provides 
interesting perspectives. The proof of principle that this innovative therapeutic strategy 
for large, complex bone defects of the maxillo-facial region is feasible and safe to 
perform, opens the possibility to treat a larger number of patients in a clinical trial. At 
the University Hospital of Basel, an estimated number of 10 to 15 patients a year would 
be eligible to be treated with this newly developed approach. Nevertheless, before 
aiming at the treatment of a larger cohort, the knowledge gained in the clinical case 
must be critically analyzed.  
It is only a speculation that the osteoblasts involved in bone formation within the 
construct originate from the seeded SVF. Even though our preclinical animal model, 
using an osteoconductive material, demonstrated that SVF cells were required for 
bone formation, it is plausible that circulating progenitors are recruited to the graft in 
response to the BMP-2 and injury [116,117]. An indicator for prominent recruitment of 
bone-remodeling (osteoblasts and osteoclasts) cells to the graft is the marked 
resorption, observed in a larger extent than in our experimental animal models. The 
BMP-2, used as a molecular trigger for progenitor cells in the SVF to undergo bone 
formation,  is known to induce resorption by attraction and activation of osteoclasts, 
especially when used in supraphysiological concentration [119]. These aspects urge 
to be investigated in an experimental animal model allowing for cell tracking and 
distinction of host and donor cells.  
As described in the fifth chapter of my thesis, using an engineered matrix could provide 
the germ for bone formation avoiding the bottlenecks of freely diffusing BMP-2 and the 
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use of living cells. By presenting the biological cues required for bone formation in a 
physiological way in its ECM, both BMP-2 and living cells could become redundant. 
Mass-produced engineered and devitalized cartilaginous matrix, useable as an off-the-
shelf material, could then be implemented together with an AV bundle to provide the 
inner germ of bone and vascularization. To use engineered matrices from hBMSC as 
a standardized and controlled therapeutic instrument, the challenges linked to the 
production thereof need to be tackled. The high inter- and intradonor variability of 
hBMSC requires appropriate controls and tests to define potency of the material. In 
this regard, generation and use of a cell line, with streamlined characteristics, could 
provide the solution [120].  
As envisioned in the concept of my thesis, the AV bundle used in the clinical case 
provided a thorough vascularization of this large construct from an early time on, 
allowing revitalization of the avital material. This vital environment was permissive for 
bony remodeling with living osteoblasts and osteoclasts and yielded a functional germ 
of vascularization and bone. Finally, the highly complex logistics of this procedure, with 
harmonized surgical and tissue engineering processes, have proved to be feasible and 
would be applicable to a larger clinical trial. In planning additional cases, the processes 
may be further streamlined by knowing how to manage crucial points of the procedure.  
To conclude, the concept described in my thesis opened the way to develop an 
innovative therapeutic strategy for large and complex bone defects, which was applied 
in a one-man clinical case. In turn, the lessons learned from this first clinical application 
pave the way for the treatment of a larger number of patients with the developed 
concept. 
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